Amneal Pharmaceuticals Inc.
Rating
Updated: Aug 25, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and ...
Latest News
3 days ago · globenewswire.com
Amneal Announces FDA Approval and Launch of Lanreotide Injection- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
5 days ago · zacks.com
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
6 days ago · gurufocus.com
Amneal Pharmaceuticals Inc (AMRX) Stock Down 3.3% but Still Overvalued -- GF Score: 59/100On September 15, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 3.3% to $16.65. This decline comes amid a 52-week trading range of $9.49 to $19.26, indicat
26 days ago · zacks.com
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month LowCOCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
1 month ago · zacks.com
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate HikeA rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
1 month ago · zacks.com
5 Top-Ranked High-Efficiency Stocks Poised for Stronger ReturnsFive stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
1 month ago · zacks.com
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
1 month ago · zacks.com
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
1 month ago · zacks.com
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
1 month ago · zacks.com
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's WhyAmneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AMRX